SPONSOR
ImmunityBio, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
ImmunityBio, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Long COVID, NSCLC Stage IV.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — ImmunityBio, Inc.
How many clinical trials has ImmunityBio, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by ImmunityBio, Inc., of which 2 are actively recruiting participants. These trials cover conditions including Long COVID, NSCLC Stage IV. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does ImmunityBio, Inc. research focus on?
ImmunityBio, Inc. clinical trials span Long COVID, NSCLC Stage IV. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a ImmunityBio, Inc. clinical trial?
To participate in a ImmunityBio, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all ImmunityBio, Inc. trials with current recruitment status updated daily.
Clinical Trials by ImmunityBio, Inc.
NCT07108036 Phase 2
Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
Long COVID
NCT06745908 Phase 3
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NSCLC Stage IV
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology